Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Behbahani Ali</u>					2. Issuer Name and Ticker or Trading Symbol  CRISPR Therapeutics AG [ CRSP ]							elationship (eck all applic	cable) r	g Perso	10% Ow	ner
	EENSPRIN	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/31/2017								(give title		Other (sp below)	pecify
SUITE 6	00			4.	If Ame	ndment, I	Date (	of Original File	ed (Month/Da	ay/Year)	6. Ir	ndividual or 3	loint/Group	Filing (	(Check App	licable
(Street)	UM M	D	21093									X Form f	led by More	•	ting Person One Report	
(City)	(S	tate)	(Zip)													
		Tab	le I - Non-De	rivativ	e Se	curities	s Ac	quired, Di	sposed c	f, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/Date)					ear)   i	A. Deemed xecution Date, any Month/Day/Year)		Code (Ins				Beneficia	s ally ollowing	6. Own Form: (D) or I (I) (Inst	Direct of Birdirect Ctr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s)		"	1150. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year	Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly [	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$13.62	05/31/2017		A		15,000		(1)	05/31/2027	Common Shares	15,000	\$0.00	15,000		D	

## **Explanation of Responses:**

1. This option was granted on May 31, 2017 with respect to 15,000 Common Shares with the shares vesting in 12 equal monthly installments.

## Remarks:

/s/ Sasha Keough, attorney-in-06/02/2017 **fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.